the present invention will be further explained and demonstrated in the following examples , which do not limit in any respect the scope of the present invention . a 25 ml flask of a rotary evaporator placed in a heated water bath was charged with : the mixture was heated up to 80 ° c . whereby -- preferably under reduced pressure -- 50 % of the water was evaporated and then -- under atmospheric pressure -- heated to a temperature of 80 °- 85 ° c ., at which it was kept for 120 min until it became orange in color . the syrup - like concentrated aqueous solution was then evaporated to dryness under reduced pressure . the orange - red solid reaction product thus obtained was marked with the symbol d - 10 and saved for biological tests . a 25 ml flask of a rotary evaporator placed in a heated water bath was charged with : the mixture was heated up to 80 ° c . with stirring ( by means of rotation ), concentrated under pressure , whereby a total volume of 1 . 5 ml water was vaporized , and then treated under atmospheric pressure at a temperature of 80 °- 85 ° c . until it became light orange in color ; this took place within approx . 60 min . the reaction mixture was a syrup - like concentrated aqueous solution and was dried under reduced pressure . the resulting reaction product was a dry , yellow - orange powder . it was marked with the symbol d - 11 and saved for biological tests . a 25 ml flask of a rotary evaporator placed in a heated water bath we charged with : the mixture was heated to 85 °- 92 ° c . with stirring ( by means of rotation ). after 100 min , the solution became orange in color . the pressure was reduced and the mixture was evaporated to dryness . the reaction product on the walls of the flask formed an orange transparent layer . the reaction product was scraped off and powdered . it was marked with the symbol d - 12 and saved for biological tests . a 25 ml flask of a rotary evaporator placed in a heated waterbath was charged with : the mixture was heated up to 80 ° c ., evaporated -- under pressure -- whereby a volume of 1 . 5 ml water was vaporized , and then treated -- under atmospheric pressure -- at a temperature of 85 ° c . after 60 min . heating the mixture became orange in color ; the pressure was reduced and the resulting syrup - like concentrated aqueous solution evaporated to dryness . before the residue became definitely dry , two times 10 ml water - free ethanol were introduced into the flask and evaporated in order to eliminate residual moisture . the dry reaction product thus obtained was powdered , marked with the symbol d - 13 and saved for biological tests . in order to obtain -- in a synthetic way -- an equivalent of the biologically active fraction of a certain natural peat extract , the flask of the rotary evaporator placed in the heated water bath was charged with : the mixture was stirred by means of rotation and heated under pressure for 45 min at a temperature rising from 75 ° c . to 86 ° c . during that period , approx . 3 ml of water were evaporated and the substrates were totally dissolved . the mixture was then treated for 30 min under atmospheric pressure at a temperature of 85 °- 86 ° c . for an amadori rearrangement . during that period the solution quickly became red - brown in color . the pressure was reduced , and heating at 84 ° c . was continued , thus simultaneously evaporating the solvents . at the end of evaporation , two times 15 ml water - free ethanol were introduced and the reaction mixture was brought to dryness . the flask with the dried reaction product was placed in a desiccator over calcium chloride for 18 hours ; then the reaction product was powdered . approx . 4 . 5 g of a powdered product were obtained and marked with the symbol ek 2 - s . a portion of 4 g of this reaction product was dissolved in 20 ml of distilled water and placed on a chromatographic column of 25 mm × 330 mm size , filled with a sorbent amerlite ® xad - 2 analytical grade . the column was eluted with 0 . 4 ml / min distilled water . fractions of 10 ml volume were collected to a total volume of 450 ml . the content of the fractions was monitored chromatographically . fractions of consecutive numbers 11 - 13 were combined and evaporated under reduced pressure . these fractions were characterised by a high content of amadori rearrangement products ( confirmed with the potassium ferricyanide reduction test ). the product was saved for biological tests under the symbol of ek 2 - s - 11 . biological tests for determining the biological activity were carried out with immunised balb / c mice of both sexes , at the age of 8 - 10 weeks . immunization of mice is achieved by peritoneal administration of 0 . 2 ml of a 10 % suspension of sheep erythrocytes ( srbc ), i . e . of 6 × 10 8 cells . the erythrocytes are fixed in a sterile alsever &# 39 ; s solution of the following composition : ______________________________________glucose 2 . 05 gsodium citrate 0 . 8 gsodium chloride 0 . 42 gcitric acid 0 . 055 gredistilled water to 100 ml______________________________________ into such alsever &# 39 ; s solution , a sheep blood cell aseptic sample is introduced in a ratio of 1 : 1 and the mixture is kept for at least 3 days at + 4 ° c . the thus stabilised erythrocytes are then sampled aseptically and introduced into a phosphate buffered salt solution ( pbs ) in order to wash them out . erythrocytes are rinsed with pbs twice , and are centrifugated for 10 min at 2000 rpm . the washed out cells are used in the form of a 10 % suspension in pbs . such a suspension is used for the immunization of balb / c mice . the reaction product to be tested was administered intraperitoneally ( i . p .) or orally ( p . o .) four times at chosen doses , the first administration taking place 2 hours before immunization of the mouse with srbc , while the remaining three dosages were administered after immunization at 24 h intervals . each test group of animals was treated with different doses of the tested reaction product : 10 mg / kg , 1 mg / kg , 0 . 1 mg / kg and 0 . 01 mg / kg . a control group of animals was also immunized with srbc , but instead of the substance to be tested , 0 . 2 ml of pbs were administered at the same time intervals . each group of animals , control and tested groups , in all experiments consisted of 8 - 12 mice . on the fourth or ( in case of determination of antibodies type 7s ) tenth day after immunization , mice were slightly anesthetized with ether and exsanguinated by eyeball extirpation . the blood was collected into test tubes . next , the spinal cord was broken and spleen removed . the blood was used for obtaining the serum needed for determination of hemagglutinating antibodies of the 19s + 7s and 7s types , while spleens were used to prepare the cells useful for determination of the percentage of cells able to form e - rosettes and of hemolytic activity . for such uses , mouse spleens were comminuted . the splenocyte cells obtained were suspended in approx . 2 ml of hanks &# 39 ; medium at + 4 ° c ., layered on the ficoll - uropolin gradient of a density of 1 . 077 , and then centrifugated for 15 min at 3000 rpm at + 4 ° c . after separation from the interphase , the lymphocyte buffy coat was placed in the hanks &# 39 ; medium at + 4 ° c . and rinsed twice with centrifugation for 7 - 10 min each time at 1800 rpm . the splenocytes were then suspended in 1 ml of hanks &# 39 ; medium at such a ratio that it contained 1 × 10 6 cells . for each test , the percentage of dead cells is determined by mixing a drop of a tested suspension of splenocytes with a drop of ex tempore prepared dyestuff solution containing 4 parts of a 0 . 2 % trypan blue solution and 1 part of a 4 . 25 % nacl solution . under the microscope , the percentage of dead splenocytes is determined for each 100 cells . dead cells are navy blue , while the bright cells are live cells . the presence of more than 10 % of dead cells is critical ; such a sample has to be eliminated from further use . all steps carried out with the cells to be tested are performed in a sterile , siliconized laboratory glass apparatus placed in an ice bath . in the first test , an effect of the tested reaction products on the number of cells producing hemolytic antibodies ( pfc - igm ) was determined . the test was carried out as follows : to 0 . 5 ml of an 0 . 5 % agarose solution placed in a test tube and kept in a heated water bath at 45 ° c ., 0 . 1 ml of a 10 % suspension of srbc ( prepared as described above ) were admixed . then 0 . 1 ml of a splenocyte suspension having a density of 1 × 10 6 cells / ml was added , the mixture stirred rapidly and immediately poured out on slides previously covered with agarose . the slides are incubated at 37 ° c . for two hours . next , the tested samples are covered with guinea pig complement diluted at a ratio of 1 : 20 for a further 2 h . after the incubation of the tested samples with the complement , the number of plaque forming cells ( pfc ) was counted and recalculated for 1 × 10 6 splenocytes . each test was performed twice . the strongest amplification of the response to srbc expressed in terms of increase of the number of splenocytes producing hemolysines igm ( pfc ) was observed after administration of the d - 11 substance at a dose of 0 . 1 mg / kg . the amplification was 119 %. when the daily dose was increased ten times up to 1 mg / kg , amplification of the response was lowered to 53 %. reaction product d - 12 showed the strongest activity -- an increase of 58 %-- at a dose of 1 mg / kg . reaction product ek 2 - s - 11 in this test showed the strongest activity at a dose of 0 . 1 mg / kg ( increase of 65 %). at a dose ten times higher , i . e . 1 mg / kg , the increase was slightly lower , i . e . 52 %. reaction product d - 13 tested at a dose of 1 mg / kg caused an increase of 40 %. when the dose was increased to 10 mg / kg , i . e . ten times , the response was only a 14 % increase . an active hemagglutination test was also carried out , determining the level of the anti - srbc type 19s - 7s and 7s the level . in order to determine the 19s - igm type antibodies level , mouse serum was prepared on the fourth day after immunization with srbc , while for the determination of 7s - igg type antibodies level such preparation took place on the tenth day after mice immunization with srbc , which is related to the day of maximum count of antibodies of a given type in mice immunized with srbc . a sample of blood was centrifuged for 30 min at 3500 rpm . from each sample thus prepared , serum was collected and placed in a heated water bath at a temperature of 56 ° c . for 30 min in order to deactivate the complement . next , a number of solutions at several different dilutions of each tested serum was prepared ( from 1 : 1 to 1 : 4096 ) employing a microtitrator and u - shaped microplates having a volume of 250 μl each . the diluted sera were incubated for 1 hour at room temperature . a drop of a 1 % suspension of srbc in pbs ( prepared as described above ) was added to each serum ; the mixtures were incubated for a further 2 h at a temperature of 37 ° c . and then stored at a temperature of + 4 ° c . the results were taken next day . the maximum dilution at which hemagglutination is still caused was considered the anti - body . count . a ring at the bottom of the plate is a sign that hemagglutination occurs . a button - like formation at the bottom of the plate is considered as a negative result -- no hemagglutination . for statistical analysis of the results , the increase of dilution of serum in a tested substance was compared to the one in a control group . reaction product d - 11 at a dose of 1 mg / kg increased the igm count 2 . 57 times . at a ten times higher dose , the stimulation effect in comparison to the control group increased by 3 . 5 times . reaction product d - 12 in this test showed a weaker activity . at a dose of 0 . 1 mg / kg , it increased the igm count 2 times , and at a dose of 1 mg / kg 1 . 4 times . reaction product ek 2 - s - 11 showed the strongest activity in this test . at a dose of 0 . 0 mg / kg , it increased the igm count 4 . 3 times , and at a dose of 1 mg / kg 3 . 6 times . reaction product d - 13 at a dose of 1 mg / kg increased the igm count 3 times , and at a ten times higher dose 1 . 5 times . the tested inactivated sera were combined -- at a ratio of 1 : 1 -- with a 0 . 1 m solution of 2 - mercaptoethanol and the mixtures incubated for 30 min at a temperature of 37 ° c . 2 - mercaptoethanol destroys immunoglobulins of the 19s -( igm ) type , while immunoglobulins of the 7s -( igg ) type are not susceptible to the action of 2 - mercaptoethanol . after 30 min of incubation , the reduction reaction was stopped by means of cooling down to a temperature of + 4 ° c . for 15 min . next , a number of dilutions was prepared in a similar manner as described above with respect to determining the 19s - antibody count and combined with a 1 % suspension of srbc ; after 2 hours of incubation at 37 ° c ., the samples were stored at a temperature of + 4 ° c . the results were evaluated on the following day , according to the criteria of determining the hemagglutination count described above . simultaneously , a control test was carried out with a combination of a 1 % suspension of srbc with pbs in a ratio of 1 : 1 . when the substance d - 11 was tested as described above , at a dose of 1 mg / kg it increased the production of antibodies igg 3 . 16 times . at a dose of 10 mg / kg , the increase was 2 . 2 times . reaction product d - 12 tested at a dose of 0 . 1 mg / kg and 1 mg / kg respectively stimulated the production of antibodies igg 1 . 3 times , and at a dose of 10 mg / kg 1 . 5 times . reaction product ek 2 - s - 11 at a dose of 0 . 1 mg / kg stimulates the production of igg 1 . 9 times , and at a dose of 1 mg / kg 2 . 89 times ( in comparison with the control ). the results of tests a and b obtained for each production lot or for each fraction of the biologically active reaction products synthesized according to the invention and giving the above - mentioned immunological response were subjected to statistical analysis by the t - student method , α = 0 . 05 . results obtained for each dose tested were compared with a parallel control test and showed an increase of biological activity . the group of biologically active reaction products obtained according to examples 1 to 5 have also been submitted to the test in which the percentage of splenocytes forming e - rosettes was determined . 250 μl of a 1 % suspension of srbc and 250 μl of cells to be tested at a concentration of 1 × 10 6 cells / ml were added to 550 μl of hanks &# 39 ; medium . each such samples was incubated in a heated water bath equipped with a shaker for 15 min at a temperature of 37 ° c . then , it was stored at a temperature of + 4 ° c . for a further 20 h . the percentage of splenocytes forming e - rosettes with srbc was determined after the suspension was colored with 1 to 3 drops of crystal violet . each sample was subjected to determination of the percentage of splenocytes three times , counting at each instance 400 splenocytes . a splenocyte surrounded with at least 3 erythrocytes was considered an e - rosette . for statistical evaluation , the percentage increase of the number of splenocytes with e - rosettes was compared between the substances to be tested and a control group . in this test , the strongest stimulating effect was shown by the reaction products d - 11 ( 63 %) and ek 2 - s - 11 ( 70 %) at a dose of 1 mg / kg . at a dose ten times smaller , i . e . 0 . 1 mg / kg , the values decreased to 45 % and 57 % respectively . reaction product d - 12 at a dose of 1 mg / kg caused an increase of the ability to form e - rosettes of 22 % in comparison to the control group . the respective value for a dose ten times smaller , i . e . of 0 . 1 mg / kg , was 29 %. reaction product d - 13 shows the maximum effect at a dose of 1 mg / kg ( 58 %), while at higher doses the effect is slightly smaller . biological activity of synthesized compounds was evaluated according to the following tests : 1 . test for determination of the percentage of splenocytes forming e - rossettes , carried out according to bach and dardenne ( cell . immunol . 3 , 1 - 16 , 1972 ) 2 test for determination of the number of cells producing hemolytic antibodies of an igm type , carried out according to the jerne method , modified by mishell and dutton ( j . exp . med . 126 , 423 - 442 , 1967 ) and 3 . test for determination of a hemagglutination 19s - 7s and 7s antibody count , carried out according to adler &# 39 ; s active hemagglutination methods ( j . immunol . 95 , 26 - 38 , 39 - 47 , 1965 ) with the use of microplates ( j . immunopharmacol . 4 , 43 - 52 , 1982 ). a rotary evaporator flask placed in a heated water bath was charged with : 10 . 00 g hydrolyzed dextrane of an average molecular weight of 3000 daltons the mixture was heated under pressure at a temperature of 70 ° c . until the solid substances were completely dissolved , expelling by means of distillation during that period approx . 3 ml of water ( heating time was approx . 30 min ). the flask with the solution was loosely covered , placed in a steam sterilizer and heated under pressure at a temperature of 121 ° c . for 40 min . after cooling down , the resulting yellow - orange solution was diluted with 15 ml of water , clarified by means of centrifugation and spray dried by air having an inlet temperature of - 160 ° c . and an outlet temperature of + 85 ° c . 10 . 5 g of a light beige reaction product resulted that was easily soluble in water . the presence of amadori rearrangement products in this reaction product was confirmed by a test by the potassium ferricyanide method described by borsook , abrams and lowy , j . biol . chem 215 , ( 1955 ), 111 - 124 and by chromatographic methods . biological tests as described in the preceding examples confirmed an immunotropic activity of the above product similar to the one exhibited by preparations obtained with simple sugars . 5 . 0 g hydrolyzed dextrane of an average molecular weight of approx . 5000 daltons the content was dissolved by means of stirring . the uniform mixture thus obtained was placed in a steam sterilizer and heated under pressure at a temperature of 110 ° c . for 40 min . the resulting transparent orange solution was diluted with 20 ml of redistilled water and clarified by means of centrifugation . the clear solution was spray dried . 5 . 3 g of a reaction product easily soluble in water was obtained . immunotropic activity was similar to the one observed in other experiments according to the preceding examples . conventional methods test the biological activity of the compounds in mice , but not in humans . for this reason , new bio - assays have been introduced , which measure the amounts and activity of cytokines released from the human peripheral blood leukocytes ( pbl ) treated with the reaction products according to the examples 1 to 5 , 9 and 10 . the cytokines are the hormone - like proteins that play an important role in practically all of the immunological reactions , as well as in the regulatory processes responsible for the maintenance of homeostasis . cytotoxicity of the reaction products was determined in human lung adenocarcinoma cell line a549 ( included in the american type culture collection -- atcc ccl 185 ). the cell monolayers were trypsinized , suspensions of 2 × 10 5 cells / ml in dulbecco &# 39 ; s - modified eagle &# 39 ; s minimum essential medium ( dmem ) plus 10 % calf serum ( cs ) were mixed with various doses of the drugs , seeded in the plastic microplates , and incubated for 48 h at 37 ° c . cd 50 was the minimal concentration of the compound which caused approximately 50 % destruction of the cell culture as measured by staining with 0 . 015 % solution of neutral red in dmem . buffy coats from healthy blood donors were obtained from the regional transfusion center . the erythrocytes were lysed by nh 4 cl treatment according to cantell et al . ( cantell , k ., hirvonen , s ., kauppinen , h . l . : production and partial purification of human immune interferon . meth . enzymol ., 119 , 54 , 1986 ). the leukocytes from a single donor containing approximately 8 × 10 6 leukocytes / ml in rpmi 1640 medium supplemented with 10 % fetal calf serum ( fcs ), l - glutamine , and antibiotics were used . all lots of fcs were pretested . only non - mitogenic fcs for pbl cultures was used . the cytokine inducers were added to 1 ml volumes of the cultures . the reference cytokine inducers were phytohemagglutinin ( pha ) ( pharmacia fine chemicals , sweden ) and lps from e . coli 0111 : b4 ( difco laboratories ). the induced cultures of pbl were incubated in an atmosphere of 5 % co 2 in air at 37 ° c . for 20 h and centrifuged . supernatants were stored at 4 ° c . and assayed for tnf and ifn activity within one week . the confluent monolayer of a549 cells was prepared in the microplates in dmem with 10 % cs , l - glutamine , and antibiotics ( 100 units / ml penicillin and 100 μg / ml streptomycin ). ifn samples diluted in plates were added to the cell monolayer and incubated at 37 ° c . for 20 h in 5 % co 2 in air . the cells were then washed and challenged with encephalomyocarditis virus ( emcv ). the titer of ifn was defined as the dilution of ifn sample that reduced the virus cytopathogenic effect by 50 % after 48 h of incubation . the mtt ( 3 - 4 , 5 - dimethylthiazol - 2 - yl !- 2 , 5 - diphenyltetranolium bromide ) method ( hansen , m . b ., nielsen , s . e ., and berg , k . : re - examination and further development of a precise and rapid dye method for measuring cell growth / cell kill . j . immuno . meth ., 1989 , 119 , 203 - 210 ) to measure the cell kill in the elisa scanner was also used . laboratory standards of ifns were included in all assays : recombinant human ifn - γ ( genentech inc ., usa , specific activity 2 × 10 8 units / mg ), the natural human leukocyte ifa - α ( 3 × 10 6 iu / ml ) and ifn - γ ( 2 × 10 6 iu / ml ) obtained from dr . k . cantell , helsinki , finland . the cytotoxic activity of tnf was measured in l929 cells according to flick and gifford ( flick , d . a ., gifford , g . e . : comparison of in vitro cell cytoxic assays for tumor necrosis factor . j . immunol . meth ., 68 , 167 , 1984 ). the sample and actinomycin d solution were added to monolayer cultures of the cells . after incubation at 37 ° c . for 20 h , the cultures were stained with crystal violet and toxic effects were determined . the amount causing approximately 50 % destruction of the cell cultures was defined as one unit of tnf activity . comparison with a preparation of tnf - α ( genentech inc ., usa ) showed that 1 unit in our assays was equal to 100 - 200 pg / ml tnf . the antisera used were : rabbit anti - human tnf - α , lot 2958 - 40 and rabbit anti - human ifn - γ , lot 2891 - 56 ( genentech inc ., usa ), sheep anti - human ifn - α , β , and sheep anti - human ifn - γ ( obtained from dr . k . cantell , finland ). the cytokine preparations were treated with the sera diluted 1 : 200 in culture medium and incubated for one hour at room temperature . then , the residual ifn or tnf activities were determined as described . five different batches ( l 1 to l 5 ) of pbl prepared from the blood of healthy blood donors were used . the optimal pbl concentration for the assays was found to be 8 × 10 6 cells per one ml of medium ( rpmi 1640 supplemented with 10 % fetal calf serum and antibiotics ). incubation of human pbl with the new reaction products i - xi ( table 1 ) resulted in ifn and tnf synthesis . the observed responses were dose related in the range of 3 - 100 μg / ml of the compounds ( table 2 ). the compounds used in the indicated concentrations were non - cytotoxic . in all of the bioassays , negative and positive controls were included . the negative controls measured the amounts of the cytokines ( ifn and tnf ) produced spontaneously without the addition of any exogenous stimulants . the positive controls indicated the amounts of the cytokine produced in response to a known reference inducer ; in our case this was phytohemagglutinin ( pha , pharmacia , sweden , 10 μg per ml ). it should be pointed out that the cytokine induction in human pbl cultures obtained from different individuals usually gives considerable variation of the results . the phenomenon may be explained in terms of genetic differentiation of human population . furthermore , pbl cultures often produce ifn and tnf spontaneously . in other words , high responders and low responders or even non - responders are commonly observed among the healthy donors of pbl . despite the presented limitations , the results of the bioassays showed that pbl ( l 1 to l 5 ) treated with the reaction products ( i - xi ) produced ifn and / or tnf that could be measured quantitatively . in the case of l 1 which contained leukocytes of the high responder , the reaction product ii ( containing l - form of aspartic acid ) was found to be considerably more active as a cytokine inducer than the reaction product iii ( containing the d - form of aspartic acid which also is more expensive by two orders of magnitude ). the observation is significant because mainly l - forms of the amino - acids are recognized by cells as natural substrates in biochemical reactions . furthermore , for the expression of biological activity of the reaction products , the amino - acid part of the molecule is much more important than the form of sugar . instead of single sugars ,-- preferably low molecular weight , especially of less than 1000 daltons -- polysaccharides ( such as dextranes , reaction products x - xi ) can be used and they react similarly . and vise versa , polysaccharides containing the amino - acid residues may have biological activity , and this activity is retained when they are decomposed to oligosaccharides with the bound amino - acid ( data not shown ). similar results may also be observed if a short peptide is taken instead of a single amino - acid and is used to stimulate the leukocytes to produce cytokines ( data not shown ). seven reference batches of the unfactionated ttp assayed in over 100 pbl cultures from different donors produced from 10 to 1 , 000 units of ifn per ml , and from 9 to 750 units of tnf per ml . the fraction ek 2 - s prepared from a mixture corresponding to the contents of natural peat extract ( example 5 ) has been assayed in eight pbl cultures from eight different blood donors . it was found to be the most active preparation in inducing both ifn and tnf ( data not shown ). possible applications of the reaction products are as immuno - modulators and such activity was clinically useful . tissue regeneration is another proven activity . anti - cancer activity probably connected with the presence of the induced interferon and tumor necrosis factor was also observed . anti - viral activity was also noted . the main use of the above reaction products involves oral administration , but parenteral treatment is also possible , as is , topical application . the products appear relatively stable . table 1______________________________________list of reaction productsno . substrates______________________________________i ( d - 10 ) l - glutamic acid , glucose , galactoseii ( d - 11 ) l - aspartic acid , glucose , galactoseiii ( d - 13 ) d - aspartic acid , glucose , galactoseiv ( d - 12 ) l - serine , glucose , galactosev ek . sub . 2 - s ( fractions 11 - 13 ) vi ek . sub . 2 - s ( fractions 6 - 7 ) vii ek . sub . 2 - s ( fractions 8 - 10 ) viii ek . sub . 2 - s ( fractions 28 - 34 ) ix l - proline , glucosex l - aspartic acid + dextrane ( variety 1 ) xi l - aspartic acid + dextrane ( variety 2 ) ______________________________________ pharmaceutical formulations containing as an active ingredient the reaction products according to examples 1 to 5 , 9 and 10 , were prepared using the following reaction products : 5 . 0 g of the reaction product obtained according to example 1 or 10 ( active substance ), the ingredients were mixed and granulated with 30 % aqueous ethanol in a conventional way , then dried at 40 ° c . the granules were used to prepare capsules , each containing approx . 450 mg of granules , i . e . 5 mg of the active substance . alternatively , the granules were used to form tablets , each weighing approx . 450 mg and containing 5 mg of the active substance . b . in the same conventional manner , the active substances obtained according to the preceding examples 1 to 5 , 9 and 10 were formulated into other pharmaceutical formulations using suitable carriers . table 2__________________________________________________________________________biological activity of the reaction products i - xi in human pbldose ifn units / ml inf units / mlμg / ml l . sub . 1 l . sub . 2 l l l l l l l l__________________________________________________________________________control -- 10 & lt ; 10 & lt ; 10 20 & lt ; 10 80 9 27 27 & lt ; 9pha 10 100 30 30 60 100 250 80 250 250 250i 100 100 & lt ; 10 & lt ; 10 20 -- 250 9 9 160 -- 30 -- -- -- 30 -- -- -- -- 500 -- 10 30 & lt ; 10 & lt ; 10 30 -- 80 9 18 160 -- 3 -- -- -- 10 -- -- -- -- 160 -- ii 100 100 10 & lt ; 10 10 & lt ; 10 250 18 18 250 & lt ; 9 30 -- -- -- 10 & lt ; 10 -- -- -- 250 & lt ; 9 10 1000 10 30 10 10 250 50 27 250 & lt ; 9 3 -- -- -- 10 & lt ; 10 -- -- -- 160 & lt ; 9iii 100 & lt ; 10 & lt ; 10 10 10 & lt ; 10 250 9 18 250 & lt ; 9 30 -- -- -- 30 & lt ; 10 -- -- -- 250 & lt ; 9 10 & lt ; 10 & lt ; 10 & lt ; 10 10 & lt ; 10 80 27 18 250 & lt ; 9 3 -- -- -- 10 & lt ; 10 -- -- -- 80 & lt ; 9iv 100 & lt ; 10 10 10 20 & lt ; 10 80 60 9 160 & lt ; 9 30 -- -- -- 20 & lt ; 10 -- -- -- 27 & lt ; 9 10 & lt ; 10 30 & lt ; 10 20 & lt ; 10 80 50 18 80 & lt ; 9 3 -- -- -- 20 & lt ; 10 -- -- -- 80 & lt ; 9v 100 30 & lt ; 10 & lt ; 10 60 -- 80 50 18 250 -- 30 -- -- -- 60 -- -- -- -- 80 -- 10 & lt ; 10 & lt ; 10 & lt ; 10 10 -- 80 27 9 80 -- 3 -- -- -- 10 -- -- -- -- 80 -- vi 100 & lt ; 10 & lt ; 10 & lt ; 10 20 -- 80 27 18 80 -- 30 -- -- -- 10 -- -- -- -- 80 -- 10 10 & lt ; 10 & lt ; 10 20 -- 50 27 18 160 -- 3 -- -- -- 10 -- -- -- -- 250 -- vii 100 & lt ; 10 & lt ; 10 & lt ; 10 -- -- 80 27 27 -- -- 30 -- -- -- -- -- -- -- -- -- -- 10 10 & lt ; 10 & lt ; 10 -- -- 80 27 27 -- -- 3 -- -- -- -- -- -- -- -- -- -- viii 100 & lt ; 10 & lt ; 10 & lt ; 10 -- -- 80 160 27 -- -- 30 -- -- -- -- -- -- -- -- -- -- 10 & lt ; 10 & lt ; 10 & lt ; 10 -- -- 750 80 27 -- -- 3 -- -- -- -- -- -- -- -- -- -- ix 100 10 & lt ; 10 & lt ; 10 10 -- 27 27 18 80 -- 30 -- -- -- 20 -- -- -- -- 80 -- 10 100 30 & lt ; 10 20 -- 80 27 18 80 -- 3 -- -- -- 10 -- -- -- -- 50 -- x 100 100 & lt ; 10 20 20 -- 27 27 18 250 -- 30 -- -- -- 30 -- -- -- -- 80 -- 10 & lt ; 10 10 & lt ; 10 30 -- 18 50 27 50 -- 3 -- -- -- 30 -- -- -- -- 250 -- xi 100 & lt ; 10 10 & lt ; 10 30 -- 18 27 27 50 -- 30 -- -- -- 10 -- -- -- -- 250 -- 10 & lt ; 10 30 & lt ; 10 10 -- 18 80 80 80 -- 3 -- -- -- 20 -- -- -- -- 750 -- __________________________________________________________________________ the active substances obtained according to preceding examples 1 to 5 , 9 and 10 were used as a beneficial additive to cosmetic preparations intended for everyday hair and body care , the content of the substances being within a range of 0 . 01 - 10 % by weight , depending on the type of the preparation , the method of application and the frequency of use intended for the particular preparation .
novel amadori reaction compounds have the formula r 1 -- nh -- r 2 , wherein r 1 comprises the d - form of a 1 - amino - 1 - deoxy - 2 - ketose radical derived from a sugar radical selected from the group of glucose , xylose , galactose , rhamnose , fructose , mannose , 6 - deoxyglucose , glucosamine and galactosamine , and r 2 comprises the l - form of an aminoacid or peptide radical selected from the group of serine , glycine , proline , histidine , arginine , alanine , aspartic acid , glutamic acid , phenylalanine , treonine , cysteine , cystine , glutamine , asparagine , methionine , tyrosine , hydroxyproline , tryptophane , valine isoleucine , lysine and leucine . compounds and combinations of compounds having the general formula r 1 &# 39 ;-- nh -- r 2 &# 39 ;, wherein r 1 &# 39 ; comprises a 1 - amino - 1 - deoxy - 2 - ketose radical derived from the group of simple sugars , oligo - and polysaccharides , and r 2 &# 39 ; comprises an aminoacid or a peptide radical , are used to produce pharmaceutical preparations which in contact with human leukocytes produce interferon and other cytokines .